SeaStar Medical is trading at $2.93, down 7.57%, with no clear company-specific explanation; broader market pressure is the likelier context.
- On October 22, 2026, the company reported positive pediatric QUELIMMUNE registry findings.
- Reuters cited renewed pressure from AI-spending concerns and rising oil prices amid geopolitical unease.
- Healthcare-sector strength offered a counterpoint but did not explain the decline.